(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on litigation, filed in the U.S. District Court of the District of Columbia, regarding the Trump administration’s final rule Transparency in Coverage: To avoid higher prescription drug costs for
(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing, “The Need to Make Insulin Affordable for All Americans,”
New Milliman Analysis Shows Medicare Part D Proposed Rule Could Increase Premiums More than It Saves in Cost Sharing for Majority of Beneficiaries (Washington, D.C.) — A new report, “Medicare Part D Pharmacy Price Concessions at the Point of Sale, Potential Impacts
Pennsylvania State Facts & Resources PBM Savings and Patient Impact in Pennsylvania Pharmacy benefit experts secure lower prescription drug costs and enable better health outcomes for patients. PBMs will save Pennsylvanians $45B across all Pennsylvania insurance markets over ten years
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. WISCONSIN EMPLOYERS ON WHITE BAGGING… Recently, we introduced you to the
©2024 PCMA. All Rights Reserved.
